K. Karampampa

发表

Cost of disorders of the brain in Europe 2010

J. Os, C. Faravelli, L. Fratiglioni, 2011, European Neuropsychopharmacology.

Productivity losses among people with back pain and among population-based references: a register-based study in Sweden

K. Alexanderson, N. Zethraeus, K. Karampampa, 2020, BMJ Open.

Early vs. late treatment initiation in multiple sclerosis and its impact on cost of illness: A register-based prospective cohort study in Sweden

H. Gyllensten, J. Hillert, K. Karampampa, 2022, Multiple sclerosis journal - experimental, translational and clinical.

Does a hospital admission in old age denote the beginning of life with a compromised health-related quality of life? A longitudinal study of men and women aged 65 years and above participating in the Stockholm Public Health Cohort

A. Ahlbom, P. Frumento, K. Karampampa, 2016, BMJ Open.

Health trends of the ageing population in Sweden : association of mortality reductions with morbidity and quality of life improvements

K. Karampampa, 2015 .

Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Italy

A. Gustavsson, G. Fattore, K. Karampampa, 2012, Multiple sclerosis.

Declining incidence trends for hip fractures have not been accompanied by improvements in lifetime risk or post-fracture survival--A nationwide study of the Swedish population 60 years and older.

K. Michaëlsson, A. Ahlbom, K. Karampampa, 2015, Bone.

Types of working-life sequences among people recently diagnosed with multiple sclerosis in Sweden: a nationwide register-based cohort study

K. Alexanderson, J. Hillert, K. Karampampa, 2020, BMJ Open.

Diagnosis-specific sickness absence and disability pension before and after multiple sclerosis diagnosis: An 8-year nationwide longitudinal cohort study with matched references.

K. Alexanderson, J. Hillert, K. Karampampa, 2020, Multiple sclerosis and related disorders.

Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Spain

A. Gustavsson, K. Karampampa, T. Arbizu, 2012, Multiple sclerosis.

Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from France.

L. Rumbach, A. Gustavsson, K. Karampampa, 2012, Multiple sclerosis.

Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Germany

A. Gustavsson, K. Karampampa, Michael Lang, 2012, Multiple sclerosis.

Does Improved Survival Lead to a More Fragile Population: Time Trends in Second and Third Hospital Admissions among Men and Women above the Age of 60 in Sweden

A. Ahlbom, K. Karampampa, T. Andersson, 2014, PloS one.

Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Turkey

K. Karampampa, R. Karabudak, Z. Caliskan, 2015, Journal of medical economics.

Treatment experience, burden, and unmet needs (TRIBUNE) in Multiple Sclerosis study: the costs and utilities of MS patients in The Netherlands

A. Gustavsson, J. Mostert, K. Karampampa, 2013, Journal of medical economics.

Benjamin Eckert countries Treatment experience , burden and unmet needs ( TRIBUNE ) in MS study : results from five European

A. Gustavsson, K. Karampampa, C. Miltenburger, 2012 .

Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed/refractory multiple myeloma patients in Canada and France

K. Karampampa, F. Cotté, D. Dhanda, 2023, Journal of medical economics.

Healthcare, Sickness Absence, and Disability Pension Cost Trajectories in the First 5 Years After Diagnosis with Multiple Sclerosis: A Prospective Register-Based Cohort Study in Sweden

K. Alexanderson, H. Gyllensten, J. Hillert, 2019, PharmacoEconomics - Open.

Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries

A. Gustavsson, K. Karampampa, C. Miltenburger, 2012, Multiple sclerosis.

Excess costs of multiple sclerosis: a register-based study in Sweden

J. Hillert, K. Karampampa, Alejandra Machado, 2022, The European Journal of Health Economics.

Cost-of-Illness Progression Before and After Diagnosis of Multiple Sclerosis: A Nationwide Register-Based Cohort Study in Sweden of People Newly Diagnosed with Multiple Sclerosis and a Population-Based Matched Reference Group

K. Alexanderson, J. Hillert, K. Karampampa, 2021, PharmacoEconomics.

Disease-modifying therapies and cost-of-illness progression among people newly diagnosed with multiple sclerosis: a national register-based cohort study covering treatment initiation with interferons, glatiramer acetate or natalizumab

H. Gyllensten, J. Hillert, K. Karampampa, 2023, BMJ Open.

Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada.

A. Gustavsson, K. Karampampa, D. Selchen, 2012, Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharamcologie clinique.

Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from the United Kingdom

A. Gustavsson, K. Karampampa, D. Tyas, 2012, Multiple sclerosis.

Trajectories of disposable income among people of working ages diagnosed with multiple sclerosis: a nationwide register-based cohort study in Sweden 7 years before to 4 years after diagnosis with a population-based reference group

K. Alexanderson, K. Karampampa, E. Friberg, 2018, BMJ Open.

Cost-of-illness trajectories among people with multiple sclerosis by comorbidity: A register-based prospective study in Sweden

K. Alexanderson, J. Hillert, K. Karampampa, 2020, Multiple sclerosis journal - experimental, translational and clinical.

Observational study of the implementation of telephone advice nursing in Sweden: did callers follow recommendations and did the rate of healthcare visits change?

N. Zethraeus, K. Karampampa, A. Wahlberg, 2021, BMJ Open.

Trends in age at first hospital admission in relation to trends in life expectancy in Swedish men and women above the age of 60

A. Ahlbom, K. Karampampa, T. Andersson, 2013, BMJ Open.

An indirect treatment comparison of efficacy and health-related quality of life following treatment with idecabtagene vicleucel versus belantamab mafodotin in triple-class exposed relapsed/refractory patients with multiple myeloma.

J. Braverman, K. Karampampa, D. Ayers, 2023, Leukemia & lymphoma.

Declining incidence trends for hip fractures have not been accompanied by improvements in lifetime risk or post-fracture survival--A nationwide study of the Swedish population 60 years and older.

K. Michaëlsson, A. Ahlbom, K. Karampampa, 2015, Bone.